A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Public ClinicalTrials.gov record NCT01519492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci
Study identification
- NCT ID
- NCT01519492
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Affinium Pharmaceuticals, Ltd
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- AFN-12520000 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2012
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
- Last update posted
- Aug 6, 2012
2012
United States locations
- U.S. sites
- 12
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SITE 018 | Buena Park | California | 90620 | — |
| SITE 005 | Chula Vista | California | 91911 | — |
| SITE 001 | La Mesa | California | 91942 | — |
| SITE 016 | Oceanside | California | 92056 | — |
| SITE 017 | Augusta | Georgia | 30909 | — |
| SITE 002 | Columbus | Georgia | 31904 | — |
| SITE 004 | Savannah | Georgia | 31406 | — |
| SITE 006 | Las Vegas | Nevada | 89109 | — |
| SITE 003 | Somers Point | New Jersey | 08244 | — |
| SITE 007 | Cincinnati | Ohio | 45267 | — |
| SITE 011 | Toledo | Ohio | 43608 | — |
| SITE 008 | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01519492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2012 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01519492 live on ClinicalTrials.gov.